Related Articles
Managing anemia in MF, key emerging trials in the UK, and approaching young patients with MPNs
Myelofibrosis (MF) is a hematologic malignancy that causes progressive bone marrow fibrosis and presents with other clinical manifestations, including anemia…
VJHemOnc – The video journal of hematological oncology
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve…
Current trials in MPN in the UK and the launch of the myMPNVoice app
Claire Harrison, MD, FRCP, FRCPath, Guy’s & St Thomas’ NHS Foundation Trust, London, UK, provides a comprehensive overview of the current key trials in the…
VJHemOnc – The video journal of hematological oncology
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve…
Current SoC for BPDCN and other emerging treatment options
Cristina Papayannidis, MD, PhD, University of Bologna, Bologna, Italy, summarizes the current standard of care (SoC) for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).…
BSH 2024 | VJHemOnc
The 64th Annual Scientific Meeting of the British Society for Haematology (BSH) took place on 28-30 April 2024 in Liverpool, UK, and brought together hematology…
Case Study: AML diagnosis, classification, risk-stratification and treatment
Sanam Loghavi and Naval Daver discuss the current approach to the diagnosis and classification, risk-stratification and treatment options for newly diagnosed AML in the context…
Using MRD to guide treatment decisions in myeloma
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the potential for using measurable residual disease (MRD) status to…
The current treatment approaches for patients with VEXAS syndrome
Maël Heiblig, MD, Hôpital Lyon Sud, Lyon, France, discusses the current treatment approaches for patients with VEXAS syndrome, which include controlling inflammation, controlling the clone,…
FDA approves fidanacogene elaparvovec, a one-time gene therapy, for adult patients with hemophilia B
Read about the FDA approval of fidanacogene elaparvovec, a one-time gene therapy, for adults with hemophilia B.